Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats

• Autor(a) principal: de Souza, Aline
• Data de Publicação: 2024
• Outros Autores: Scarim, Cauê Benito [UNESP], Cotrim, Paulo Cesar, Junior, Fernando Barbosa, Rocha, Bruno Alves, Calixto, Leandro Augusto, Correia, Cristiano Jesus, de Barros Araújo, Gabriel Lima, Löbenberg, Raimar, Bou-Chacra, Nádia Araci, Breithaupt-Faloppa, Ana Cristina
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.2217/nnm-2023-0263; https://hdl.handle.net/11449/304183
• topic: chylomicrons; cycloheximide; hydroxymethylnitrofurazone; lymphatic system; nanostructured lipid carrier

Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.